Clicky

Pharmicell(005690)

Description: Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Biology Pharmacy Dielectric Stem Cell Liver Disease Specialty Drugs Mesenchymal Stem Cell Angioplasty Acute Myocardial Infarction Stem Cell Bank

Home Page: www.pharmicell.com

Ssangbong Building
Seoul,
South Korea
Phone: 82 2 3496 0114


Officers

Name Title
Hyun-Soo Kim Chief Exec. Officer and Inside Director
Mr. Shi-Young Jang Sr. Managing Director
Mr. Yongman Kim Sr. Managing Director
Woon-Sung Baek Sr. Managing Director
Yong-Hyun Nam Exec. Officer
Min-Seok Seo Exec. Officer
Jin-Gyoon Gwak Exec. Officer

Exchange: KO

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 8.112
Price-to-Sales TTM: 29.9459
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks